close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
Stay Informed
SCROLL
Stay Informed
SCROLL

Stay in the know by signing up to receive emails with helpful information about your Aimovig journey.

Do you have a prescription for Aimovig?
 

No problem. If you don’t have an Aimovig prescription yet, we can keep you in the loop with the latest on Aimovig and helpful resources for this stage in your journey. Simply fill out the form below.

*Required Information
*Have you been diagnosed with migraine by a doctor?
*How many days per month are you typically impacted by migraine?
*Are you currently using any preventive migraine treatments or have you used any in the last 5 years?
When it comes to migraine, who do you rely on most for information/support?
aimAlly-support-logo

The Aimovig AimAlly™ 90-Day Start Program is a simple way to get the resources and support you need to navigate your first 3 months on Aimovig, all in one place.

*Required information
You must be 18 years or older to enroll in the AimAlly™ 90-Day Start program.
*Date of Birth
Please select month

We're sorry—you must be 18 years or older.

Please enter a valid date

Please select day
Please select year
*Do you use
to pay for your Aimovig prescription at the pharmacy? This information will help us customize your emails.
 
Please select Yes or No
*When did you or when will you have your first Aimovig injection?
Please select month
Please enter a valid date
Please provide all required information above

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation or constipation associated with symptoms such as severe or constant belly pain, vomiting, swelling of belly or bloating.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.